High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer

Advanced Colon Cancer: Staging and Prognosis by CEA Test

“…In fact, it is possible to recognize subgroups in advanced disease based on neoplastic mass. This concept, which was introduced by us in a previous article [11], needs further study for clarification. It will be necessary to identify the varia bles in advanced colon cancer which indicate a large or small mass and thus a different prognosis and perhaps also a different therapy.…”

“…The WHO response classification was employed: complete response (CR); partial response (PR); stable disease (S); progressive disease (P) [10]. The treatment protocol has been described by us in a previous study [11].…”

Advanced Colon Cancer: Staging and Prognosis by CEA Test

“…In fact, it is possible to recognize subgroups in advanced disease based on neoplastic mass. This concept, which was introduced by us in a previous article [11], needs further study for clarification. It will be necessary to identify the varia bles in advanced colon cancer which indicate a large or small mass and thus a different prognosis and perhaps also a different therapy.…”

“…The WHO response classification was employed: complete response (CR); partial response (PR); stable disease (S); progressive disease (P) [10]. The treatment protocol has been described by us in a previous study [11].…”

Developments of the fluoropyrimidines as inhibitors of thymidylate synthetase: Pharmacologic and clinical aspects

“…Since 1982, a number of phase I1 studies have been reported in patients with colorectal, gastric, and more recently, breast carcinomas. In colorectal carcinoma patients who were not previously treated with chemotherapy, the mean response rate calculated from 16 available studies [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] was 31%, ranging from 15-54% (Table I). In patients who Bruckner et al [35] Madajewicz et al I371 Cunningham et al [38] Byrne et al [50] Valone et al [51] Bertrand et al 1521 Laufman et al [44] Hines et al [ were previously treated with chemotherapy [33][34][35]37,38,44, the mean response rate obtained in nine trials was 15% (range, 0-50%) ( Table 11).…”

<p>Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments</p>

“……”

Advanced Colon Cancer: Staging and Prognosis by CEA Test

“…In fact, it is possible to recognize subgroups in advanced disease based on neoplastic mass. This concept, which was introduced by us in a previous article [11], needs further study for clarification. It will be necessary to identify the varia bles in advanced colon cancer which indicate a large or small mass and thus a different prognosis and perhaps also a different therapy.…”

“…The WHO response classification was employed: complete response (CR); partial response (PR); stable disease (S); progressive disease (P) [10]. The treatment protocol has been described by us in a previous study [11].…”

Developments of the fluoropyrimidines as inhibitors of thymidylate synthetase: Pharmacologic and clinical aspects

“…Since 1982, a number of phase I1 studies have been reported in patients with colorectal, gastric, and more recently, breast carcinomas. In colorectal carcinoma patients who were not previously treated with chemotherapy, the mean response rate calculated from 16 available studies [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] was 31%, ranging from 15-54% (Table I). In patients who Bruckner et al [35] Madajewicz et al I371 Cunningham et al [38] Byrne et al [50] Valone et al [51] Bertrand et al 1521 Laufman et al [44] Hines et al [ were previously treated with chemotherapy [33][34][35]37,38,44, the mean response rate obtained in nine trials was 15% (range, 0-50%) ( Table 11).…”

<p>Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments</p>

“……”

Advanced Colon Cancer: Staging and Prognosis by CEA Test

“…In fact, it is possible to recognize subgroups in advanced disease based on neoplastic mass. This concept, which was introduced by us in a previous article [11], needs further study for clarification. It will be necessary to identify the varia bles in advanced colon cancer which indicate a large or small mass and thus a different prognosis and perhaps also a different therapy.…”

“…The WHO response classification was employed: complete response (CR); partial response (PR); stable disease (S); progressive disease (P) [10]. The treatment protocol has been described by us in a previous study [11].…”

Developments of the fluoropyrimidines as inhibitors of thymidylate synthetase: Pharmacologic and clinical aspects

“…Since 1982, a number of phase I1 studies have been reported in patients with colorectal, gastric, and more recently, breast carcinomas. In colorectal carcinoma patients who were not previously treated with chemotherapy, the mean response rate calculated from 16 available studies [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] was 31%, ranging from 15-54% (Table I). In patients who Bruckner et al [35] Madajewicz et al I371 Cunningham et al [38] Byrne et al [50] Valone et al [51] Bertrand et al 1521 Laufman et al [44] Hines et al [ were previously treated with chemotherapy [33][34][35]37,38,44, the mean response rate obtained in nine trials was 15% (range, 0-50%) ( Table 11).…”

<p>Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments</p>

“……”